TVS-MOTOR-CO
16.11.2023 15:29:29 CET | Business Wire | Press release
TVS Motor Company - a leading global automaker that operates in the two and three-wheeler segments - today announced its entry into Europe by signing an agreement for import and distribution with Emil Frey, a 100 year old enterprise and a leading name in automotive distribution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116018858/en/
Lorenz Frey-Hilti, Director, Emil Frey Group & Sudarshan Venu, Managing Director, TVS Motor Company announcing the partnership (Photo: Business Wire)
This partnership signifies a significant step towards global expansion for TVS Motor Company, leveraging Emil Frey's extensive distribution network and deep market insights in Europe. TVS Motor Company, known for its commitment to innovation and quality, is set to offer European customers a diverse range of high-performance and technologically advanced two-wheelers.
Both TVS Motor Company and Emil Frey share a commitment to responsible and sustainable mobility and place a strong emphasis on delivering impeccable customer service and satisfaction. TVS Motor Company’s focus on providing cutting-edge and pioneering solutions, combined with Emil Frey’s deep ability to understand local customers and their evolving needs has helped create a unique DNA for this partnership, which will form a strong foundation for TVS Motor’s expansion in Europe.
Emil Frey is among the largest automobile importers and retailers in Europe, serving many leading automotive brands across the region. As part of this partnership, Emil Frey Group entities will take charge of the distribution of TVS products in selected countries, utilizing their Sales, Marketing, and Service networks. Among the TVS products being made available in Europe will be TVS Jupiter 125, TVS NTORQ , TVS Raider, TVS iQube S, TVS X, TVS Ronin, TVS Apache RR 310, and TVS Apache RTR 310.
Announcing the foray into Europe, Sudarshan Venu, Managing Director, TVS Motor Company said, “This strategic alliance with Emil Frey is a crucial step in our global expansion strategy. Europe will be a key market for us, and through this partnership, we aim to bring our cutting-edge products closer to European customers. In having a partner like Emil Frey, there is a coming together of two century old, pedigreed organisations, both driven by shared values of responsible and sustainable mobility and customer service. Together, we are excited to serve customers and two-wheeler aficionados in Europe and look forward to a successful partnership.”
Lorenz Frey-Hilti, Director Emil Frey Group said, “We take great pride in forging a robust and loyal partnership between our two esteemed traditional companies in the mobility sector. Together, we seamlessly blend heritage with innovation. I am very proud that TVS Motor Company is relying on our expertise in the European market and using our distribution network to bring their great products to customers. Our two companies complement each other perfectly and I look forward to seeing this partnership flourish.”
France will be the first country for the launch, where an entire suite of TVS Motor products including ICE and EV models will be made available starting January 2024, consequent to this agreement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116018858/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom